Information  X 
Enter a valid email address

K.S. Biomedix Hldgs (FOGC)


Friday 05 July, 2002

K.S. Biomedix Hldgs

Clinical Trials

K.S. Biomedix Holdings PLC
5 July 2002

Embargoed until 0700                                                5 July 2002

KS Biomedix Holdings plc                               Tel: +44 (0) 1483 307500
Dr Steven Powell, Chief Executive Officer

Weber Shandwick Square Mile                          Tel:  +44 (0) 20 7950 2800
Kevin Smith
Graham Herring

  KS Biomedix to Commence Clinical Study of TransMID(TM) in children with brain

Guildford, UK... KS Biomedix Holdings plc ('KSB' or 'the Company') (LSE: KSB)
today announced that it had received approval from the US Food and Drug
Administration ('FDA') to commence a Phase I study of TransMID(TM) in children
with malignant brain tumours.

The study will assess the safety of increasing doses of TransMID in up to 30
children aged 5 to 18 years with progressive or recurrent high-grade gliomas.
TransMID(TM) will be infused directly into the tumour on two occasions separated
by 6 to 10 weeks.  In addition to safety, the effect of TransMID(TM) on the size
of the tumour will be assessed, and the duration of any response will be
recorded.  It is hoped that, as in the studies conducted in adults, patients who
respond will survive for longer.  The study will be undertaken at two leading
cancer treatment centres in the USA.

Cancers of the brain and central nervous system are second only to leukaemia as
the most common cause of death from cancer in children. Over half of all brain
cancers in children are gliomas. While treatments that combine surgery,
radiation treatment and chemotherapy prolong survival for a majority of
children, most survivors will experience learning difficulties or other
impairments. As TransMID(TM) is administered directly into the tumour, it is not
expected to produce the widespread side effects of current treatments therefore
helping to maintain the best quality of life possible for the child.

TransMID(TM) is a novel product, based on the transferrin-mediated delivery of a
diphtheria toxin, which is capable of selectively killing cancer cells. As
reported previously, TransMID(TM) has already produced excellent response rates
and improved survival times in adult patients with highly aggressive forms of
brain cancer in two clinical studies performed in the USA.

The FDA granted Fast Track status for TransMID(TM) in August 2001 and Orphan Drug
Status for the treatment of malignant tumours of the central nervous system in
December 2001.  The European Medicines Evaluation Agency's ('EMEA') Committee
for Orphan Medicinal Products granted Orphan designation for the treatment of
glioma in March 2002.

Commenting on today's announcement, Dr Steven Powell, Chief Executive of KSB,
said: 'Extension of the TransMID(TM) trials into paediatric patients is the next
step in our development programme. In this latest study we hope to build on the
positive results reported in our previous adult trials, which showed clinically
significant improvements in both overall survival and response rate.  A pivotal
Phase III clinical trial of TransMID(TM) in adult patients is scheduled to
commence in the second half of 2002.'


Notes to Editors

KS Biomedix Holdings PLC (Guildford, UK) is a biopharmaceutical company
headquartered in the UK that is developing a broad late-stage pipeline of drugs
for a range of cancer indications. In addition, it has a number of technology
platforms based on its range of receptor-based targeting technologies one of
which is KSB's super high-affinity monoclonal antibodies (SMAs).  The Company
has seven products in or about to commence clinical trials including
TransMID-107R(TM) for the treatment of adult, recurrent, inoperable high-grade
gliomas (brain tumours), and KSB303, an anti-CEA antibody for the diagnosis and
treatment of cancer.

KS Biomedix was founded in 1993 and floated on the Alternative Investment Market
of the London Stock Exchange in 1995.  The Company joined the Official List of
the London Stock Exchange in 1998.

For more information please see

                      This information is provided by RNS
            The company news service from the London Stock Exchange

a d v e r t i s e m e n t